Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Scleritis or episcleritis)
2,107 results
  • Pattern of Scleritis in an Egyptian Cohort. [Journal Article]
  • OIOcul Immunol Inflamm 2018 Nov 09; :1-7
  • Abd El Latif E, Seleet MM, … Abdelmonagy Ibrahim M
  • CONCLUSIONS: The visual prognosis of an eye with scleritis varies with the subtype of scleral inflammation. In our cohort, it was found to be poorer in eyes with necrotizing scleritis with inflammation compared to other subtypes.
  • Clinical features of Chinese patients with relapsing polychondritis. [Journal Article]
  • BJBr J Ophthalmol 2018 Oct 12
  • Yang P, Yuan W, … Kijlstra A
  • CONCLUSIONS: Our study shows that uveitis associated with RP may manifest as generalised, anterior or posterior uveitis. The incidence of inner ear involvement and arthritis in these patients was lower than that in Caucasians. Female patients seem to have milder inflammation and a better visual prognosis.
  • Histoplasmosis following Systemic Immunomodulatory Therapy for Ocular Inflammation. [Journal Article]
  • AJAm J Ophthalmol 2018 Oct 08
  • Starr MR, Smith WM
  • CONCLUSIONS: Ocular inflammation patients on systemic immunomodulatory therapy may develop pulmonary or disseminated histoplasmosis. Most cases require treatment with systemic anti-fungal medication, but it might not be necessary to stop systemic immunomodulatory medication for ocular inflammation. Ophthalmologists should be aware that patients receiving systemic immunomodulatory therapy have a higher risk of developing Histoplasma infections. Prompt diagnosis and treatment utilizing the expertise of an infectious diseases specialist may ensure low mortality for these patients.
  • Drug-induced uveitis. [Review]
  • COCurr Opin Ophthalmol 2018; 29(6):588-603
  • Moorthy RS, Moorthy MS, Cunningham ET
  • CONCLUSIONS: The ever-broadening scope of pharmaceuticals now available to treat previously untreatable conditions, such as advanced metastatic cutaneous melanoma, have resulted in unintended ocular inflammatory diseases. Ophthalmologists must recognize that drugs such as ICPIs, BRAF, and MEK inhibitors, anti-vascular endothelial growth factor agents, tumor necrosis factor-α inhibitors, cidofovir, bisphosphonates, topical prostaglandin analogues, topical brimonidine, BCG vaccination can cause of uveitis. Utilizing a thorough review of systems, physicians may readily identify medications that may cause uveitis and avoid expensive and unnecessary laboratory testing.
New Search Next